This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Medivo Raises $15 Million To Further Expand Analytics Platform

Stock quotes in this article: SFE

Medivo Inc., a health monitoring platform that regularly connects doctors, consumers and clinical labs, today announced that it raised a $15 million Series B financing round led by the Merck Global Health Innovation Fund (GHIF), with participation from existing investors Safeguard Scientifics, Inc. (NYSE:SFE) and MentorTech Ventures.

To date, Medivo has raised more than $22 million to support its analytics capabilities and innovative health data platform, including a $7 million Series A financing in late 2011.

“We are extremely pleased to receive this additional capital to support our rapid growth,” said Sundeep Bhan, Chief Executive Officer and a Co-Founder of Medivo. “For the past three years, Medivo has doubled its growth year-over-year and is well-positioned for continued growth. The new round of funding will be used to continue expanding our clinical data platform, enriching our analytics services and building out connectivity to additional data sources. We also will broaden and enhance our product offerings for physicians and consumers, and develop new patient engagement services.”

In the past 12 months, Medivo has significantly expanded its healthcare professional and consumer reach, increased its engagements with leading life sciences companies, presented peer-reviewed findings from a proprietary clinical database, and formalized a partnership with the American Association of Clinical Endocrinologists (AACE) to deliver Medivo services to AACE members.

The Medivo HIPAA-compliant platform includes modules for physicians and patients with diabetes, dyslipidemia, hepatitis C, gout, low testosterone, irritable bowel disease, hereditary angioedema, and chronic myelogenous leukemia. Initiatives are under way to continue to expand the company’s network of laboratories and health monitoring modules, including obesity, rheumatoid arthritis, hepatitis B, HIV, colon cancer, breast cancer, prostate cancer, myelofibrosis, multiple myeloma, growth hormone deficiency, osteoporosis, hypothyroidism, and multiple sclerosis.

“Health information technology is one of the prime investment areas for Merck's Global Health Innovation Fund, and Medivo’s technology and analytics platform are at the forefront of innovation in this space,” said Joe Volpe, Investment Principal for GHIF. “We also are impressed with the team at Medivo and believe they have the experience and the track record to scale a leading health tech company.”

“Medivo continues its game-change proposition allowing physicians and patients to make better use of diagnostic test information to improve outcomes,” added Gary J. Kurtzman, MD, Managing Director, Healthcare at Safeguard. “We are pleased to have been able to provide support as the company built out its platform, and this new round of funding will enable Medivo to expand and continue on its impressive growth trajectory. We are excited to welcome Merck GHIF to the team.”

With Medivo’s access to clinical data and advanced analytics, Medivo is uniquely positioned to provide actionable insights to healthcare professionals and consumers, resulting in simplified and improved health interactions.

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,857.33 -185.57 -1.09%
S&P 500 1,957.27 -15.02 -0.76%
NASDAQ 4,446.0810 -47.3090 -1.05%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs